Parenteral Manual

Tigecycline (NON-FORMULARY)

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Glycylcycline Antibiotic
Original Date: 
April 2008
Revised Date: 
September 2011
  • Treatment of complicated skin and skin structure infections caused by susceptible organisms
    (includes gram positive, gram-negative and anaerobes)
  • Treatment of complicated intra-abdominal infections
Reconstitution and Stability: 
50 mg 5.3 mL 10 mg/mL
  • Gently swirl to dissolve  - immediately withdraw dose from vial and further dilute
  • Diluted solution stable 6 hours at room temperature or 24 hours in fridge
  • Reconstituted solution should be yellow-orange in colour;  if not,discard

-Solutions Compatible:  D5W, 0.9% NaCl, ringer's lactate

-Additives/Above Cassette Compatible:  no information

-Y-site Compatible:  amikacin, dobutamine, dopamine, gentamicin, lidocaine, morphine, norepinephrine, piperacillin/tazobactam, potassium chloride, propofol, ranitidine,  tobramycin

-Incompatible:  amphotericin B, chlorpromazine, methylprednisolone, voriconazole


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Direct NO
IV Intermittent Infusion YES
Usual dilution: in 100 mL minibag of NS 
Infusion time: over 30 - 60 minutes
IV Continuous Infusion NO

(For neonatal dosages, refer to Neonatal IV Drug Manual.)


  • safety & efficacy not established in children

Adolescent / Adult:

  • 100 mg IV  initial dose, then 50 mg IV Q12H for 5 to 14 days
  • No dosage adjustment required for renal impairment or after hemodialysis
  • No dosage adjustment required for mild to moderate hepatiac impairment
  • For severe  hepatic impairment:   100 mg IV  initial dose then 25 mg IV Q12H
Potential hazards of parenteral administration: 
  • Most common:  nausea, vomiting, diarrhea
  • Local reactions at the IV infusion site:  edema, pain
  • Hypersensitivity reactions
  • Monitor INR when used concomitantly with warfarin -  decreased clearance of warfarin
  • Structurally similar to tetracycline-  therefore, not recommended for use in children<8 or in pregnancy.  Permanent discoloration of the teeth may occur if used during tooth development.

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.